Silexion Therapeutics (SLXN) Stock Price, News & Analysis

Company Overview

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Key Stats

• Today's Range: $0.59 to $0.64
• 50-Day Range: $0.60 to $1.96
• 52-Week Range: $0.47 to $22.36
• Volume: 111,869 shs
• Average Volume: 80,732 shs
• Market Capitalization: $2.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Silexion Therapeutics Stock Analysis - MarketRank™

Silexion Therapeutics scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Silexion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Silexion Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Silexion Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Silexion Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Silexion Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.76% of the float of Silexion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Silexion Therapeutics has a short interest ratio ("days to cover") of 0.66, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Silexion Therapeutics has recently decreased by 6.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Silexion Therapeutics does not currently pay a dividend.

Dividend Growth

Silexion Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Silexion Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Silexion Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Silexion Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.00% of the stock of Silexion Therapeutics is held by insiders.

Percentage Held by Institutions

10.95% of the stock of Silexion Therapeutics is held by institutions.

SLXN Stock Analysis - Frequently Asked Questions

How have SLXN shares performed this year?

Silexion Therapeutics' stock was trading at $1.92 on January 1st, 2026. Since then, SLXN stock has decreased by 68.6% and is now trading at $0.6027.

How were Silexion Therapeutics' earnings last quarter?

Silexion Therapeutics Corp (NASDAQ:SLXN) announced its earnings results on Wednesday, November, 12th. The company reported ($2.88) earnings per share for the quarter, beating analysts' consensus estimates of ($3.40) by $0.52.

When did Silexion Therapeutics' stock split?

Silexion Therapeutics's stock reverse split before market open on Sunday, July 27th 2025.The 1-15 reverse split was announced on Sunday, July 27th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, July 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Silexion Therapeutics?

Shares of SLXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Silexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Silexion Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), Baidu (BIDU).

Company Calendar

• Last Earnings: 11/12/2025
• Today: 5/05/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLXN
• Previous Symbol: NASDAQ:SLXN
• CIK: 2022416
• Web: silexion.com
• Phone: 972-2-674-3430
• Fax: 212-572-6395
• Employees: N/A
• Year Founded: 2024

Profitability

• EPS (Trailing Twelve Months): ($11.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.91 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -387.82%
• Return on Assets: -144.68%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 2.41
• Quick Ratio: 2.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.83 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 3,330,000
• Free Float: 3,164,000
• Market Cap: $2.01 million
• Optionable: N/A
• Beta: -0.29